Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | SCN9A | Q15858 | 13/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | SCN10A | Q9Y5Y9 | 3/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | LIPE | Q05469 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4190922 | 0.95 | MAPK1 (0.55) | MAPK1HPGDSCN9ALMNASCN10A | |
| SCHEMBL14810517 | 0.90 | MAPK1 (0.51) | MAPK1HPGDSCN9ALMNASCN10A | |
| SCHEMBL1012278 | 0.89 | MAPK1 (0.50) | MAPK1HPGDSCN9ALMNASCN10A | |
| SCHEMBL30677804 | 0.87 | MAPK1 (0.64) | MAPK1HPGDSCN9ASCN10ATHRB | |
| SCHEMBL1009588 | 0.87 | MAPK1 (0.64) | MAPK1HPGDSCN9ASCN10ATHRB | |
| SCHEMBL1011518 | 0.86 | MAPK1 (0.47) | MAPK1HPGDSCN9ALMNASCN10A | |
| SCHEMBL1011905 | 0.82 | MAPK1 (0.69) | MAPK1HPGDSCN9ALMNATHRB | |
| SCHEMBL1010121 | 0.82 | MAPK1 (0.69) | MAPK1HPGDSCN9ALMNATHRB | |
| SCHEMBL27072759 | 0.77 | MAPK1 (0.63) | MAPK1HPGDSCN9ASCN10ATHRB | |
| SCHEMBL4187097 | 0.77 | MAPK1 (0.62) | MAPK1HPGDSCN9ALMNATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8044052-B2 | Inhibitors of fatty acid amide hydrolase; N-pyridin-3-yl-4-(3-{[5-(trifluoromethyl)pyridin-2-yl]oxy}benzylidene)piperidine-1-carboxamide; elevate brain anandamide levels; pain, urinary incontinence, cognitive disorders, anxiety, depression, sleeping, eating, movement disorders, glaucoma, psoriasis | PFIZER INC. (US) | 2011-10-25 | — | — | US | disclosed |
| EP-2076508-B1 | BIARYL ETHER UREA COMPOUNDS | PFIZER PROD INC (US) | 2011-01-05 | — | — | EP | disclosed |
| US-20080261941-A1 | Biaryl Ether Urea Compounds | Jazz Pharmaceuticals Therapeutics, Inc. | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261941-A1 | Biaryl Ether Urea Compounds | FAAH, FAAH2, LIPC | MAPK1 3199/4885HPGD 932/4885SCN9A 2757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.